about
Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarctionA Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical TrialsStatistical approaches for evaluating body composition markers in clinical cancer research.Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.Statistical methods applied to omics data: predicting response to neoadjuvant therapy in breast cancer.The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individualsSkin cancers associated with HIV infection and solid-organ transplantation among elderly adults.When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.Skin cancers associated with autoimmune conditions among elderly adults.Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditionsMissed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study.Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.Comparison of dynamic treatment regimes via inverse probability weighting.Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patientsEpidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States.Observation plans in longitudinal studies with time-varying treatments.Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer.Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma.Nail toxicities induced by systemic anticancer treatments.Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy.Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.Impact of dermatologic adverse events induced by targeted therapies on quality of life.How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates.Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials.Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.Uncovering Professional Attitudes Toward Treatment of Rare Carcinomas of the Breast: An International Practice e-Survey Involving 32 Countries.Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience.Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study.Lack of regression of anal squamous intraepithelial lesions despite immune restoration under cART.The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study.Distribution, characteristics, and prognostic of AIDS and non-AIDS cancers in HIV-infected patients, the ONCOVIH study.Epidemiology of non-keratinocytic skin cancers among persons with AIDS in the United States.Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
P50
Q28220222-A98D7FC7-E3A4-4C5C-8313-A2E4F650B654Q28551817-9757980C-8262-483D-8FF9-24C5CA46CB22Q30235361-B55334A5-492D-47B9-926E-FB4F718A5203Q30251438-2C9279A4-4A19-46B0-BBA3-D9FAA4B316FFQ30850557-C56B3BDD-E56F-494D-8F2E-7366101EBEE4Q33505475-73C03D75-8E01-42F1-A65F-F33E85E015CAQ33636436-CFD0263A-EC80-4A99-8C6C-B09AC353D899Q33876261-2FFD8A46-5E41-41C6-A98A-30070DC5FE2BQ33952562-810614F9-4B34-4E84-B643-BE1EBFECF7A2Q33980117-96E35FDB-B7DC-446E-B0D1-1DE59C70B166Q34702924-C6245A25-72D4-417F-84FE-EBE775B57FD6Q35065073-EF694461-1E2F-4086-ABDD-488FAF8C9B7BQ35114512-ACCD33FE-5121-46E6-9005-2BAF0B5D386FQ36447516-5A7EA10F-6372-4682-836A-7FDAFF1989E8Q37098427-98FB7D9F-6EC7-49BF-8391-1FFD5F56E155Q37295412-89814A5F-61E2-4A35-A56B-22570E53FF47Q37309589-BB8AF908-39A9-4457-A812-D21157D0F461Q37425787-3BF4C0C6-3D71-4E27-A10B-3BB96289F0F1Q37967559-BEC58D53-FC79-41E7-B468-EEF9B5563B65Q38159928-572704F2-A3B9-44D0-BB48-43D5E3BB3B50Q38176985-BC2BE235-7169-4699-A234-3784847F349DQ38407612-692C6606-4AA0-421C-A856-97A2251273E4Q38457311-39BF8311-3854-428F-9F79-7AD6D5D059A1Q38636711-546F4356-AF55-4F1F-AF6E-0A1A2E819BD6Q38781718-A8EA6A89-E0E8-4FBC-857A-D8C75A1DEA81Q39160069-F671DBBD-1D53-40C8-A4D9-28A6E5FF81AFQ39470173-28BD28AD-04CD-461E-83B9-712D8FBB2345Q39545667-6C5593C3-59DC-4AF4-8DDB-C07453AE4571Q39648893-C5559B0B-07BF-4DAB-B1C6-8B0FA72258AEQ39846121-A599BB4E-274C-403D-9316-078C5374CB4DQ40262479-85E5B681-88C5-4781-B951-FE7E03BC02F6Q40382207-CC105D62-117C-42EA-97EF-2D583CC0C48CQ40393232-B4E131AA-42A5-42B1-9D84-82AB3CAE62C7Q40539792-592F4502-EA50-4AB2-8D00-09F61AE0A0E4Q40985350-57402852-6301-4D67-8909-BB18EFD3A07DQ44540160-C1389AFB-E958-4B52-ADA3-9B5246F77D5BQ44626217-35CCDF62-09A7-4FA7-B878-690016CFA69FQ46045581-B5866041-FCE2-43C2-A85B-700DE5A37F56Q46139494-2D339C44-01F8-4B94-9CD7-EA1ECAA224EFQ46299111-1CC102C4-CF73-4D17-9630-F4C49E46F3D7
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Emilie Lanoy
@ast
Emilie Lanoy
@en
Emilie Lanoy
@es
Emilie Lanoy
@nl
Emilie Lanoy
@sl
type
label
Emilie Lanoy
@ast
Emilie Lanoy
@en
Emilie Lanoy
@es
Emilie Lanoy
@nl
Emilie Lanoy
@sl
prefLabel
Emilie Lanoy
@ast
Emilie Lanoy
@en
Emilie Lanoy
@es
Emilie Lanoy
@nl
Emilie Lanoy
@sl
P106
P21
P31
P496
0000-0002-4789-7770